Hawaii Biotech, Inc. Completes Dosing of Phase 1 Trial for West Nile Virus Vaccine

HONOLULU--(BUSINESS WIRE)--Hawaii Biotech, Inc. announced today that it has completed dosing of healthy subjects in a multiple dose safety study of its West Nile Virus vaccine. President and CEO Elliot Parks, Ph.D., indicated that preliminary safety results and immunologic data from the 24 subjects treated with three doses of the vaccine will be available early in 2009. Complete results are expected to be announced by third quarter 2009. “The trial has gone very well and we are excited to analyze the complete safety and immunologic data,” said Dr. Parks.